Ranibizumab for the Inhibition of Neovascularization in Pterygia

Completed · Phase 1

Conditions studied: Pterygium

In brief

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.

Key facts

Study ID

NCT00768963

Run by

University of Miami

People needed

10

Starts

2008-10-01

Expected to finish

2012-01-01

Last updated by the study team

2017-07-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects will be eligible if the following criteria are met:
• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age > 18 years
• Patient related considerations: All patients of both genders will be considered for enrollment.
• Disease related considerations:
• Patients with pterygia will be considered for enrollment if the pterygium meets standard pterygium excision criteria including encroachment into the visual axis
• severe induced astigmatism
• foreign body sensation unresponsive to medical therapy.

You may not qualify if…

• Subjects who meet any of the following criteria will be excluded from this study:
• Pregnancy (positive pregnancy test)
• Women seeking to become pregnant
• Lactating women
• Prior enrollment in the study
• Prior glaucoma surgery in the region of the pterygium
• Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
• Participation in another simultaneous medical investigation or trial

Where it is running

• Bascom Palmer Eye Institute — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.